EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease

Raphael Loisl, Anna Bauhofer, Alexander Nikoloudis, Robert Milanov, Sigrid Machherndl-Spandl, Veronika Buxhofer-Ausch, Michaela Binder, Petra Hasengruber, Emine Kaynak, Dagmar Wipplinger, Irene Strassl, Olga Saini und 5 weitere

Annals of Hematology · 06.08.2026 · 105 (8)

DOI: 10.1007/s00277-026-07217-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 06.08.2026. Verfasst von Raphael Loisl und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethine…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Pyrazoles, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Regensburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Steroid-refractory (SR) acute and chronic graft-versus-host disease (aGVHD/cGVHD) are frequent and serious complications after allogeneic hematopoietic stem cell transplantation. Ruxolitinib (RUX) is approved for the treatment of both conditions. Real world evidence may provide valuable complementary information beyond prospective trials because of significant divergences in study populations, endpoints, treatment strategies, and observation time. We report long-term outcomes of 118 patients with acute (n = 61), classic chronic (n = 43) and overlap chronic GVHD (n = 14) who received RUX within a named-patient-program in the pre-approval era as second-line treatment or beyond. In 22 patients, GVHD occurred after donor lymphocyte infusion (DLI). The cohort included heavily pretreated patients, with 26.2% of aGVHD in 3rd -line or beyond, and 29.8% of cGVHD in 4th -line or beyond. Only 22 patients (18.6%) met all in-/exclusion criteria of the respective pivotal phase III studies. The most frequent incompatibilities were unmet SR criteria, excessive pretreatment, previous DLI, overlap chronic GVHD, and medical/hematological criteria. Overall response rate to RUX was 68.9% in aGVHD, and 66.7% in cGVHD. In all three GVHD types, > 50% of patients were able to discontinue systemic steroids. With a survivors’ median follow up of 60.3 months (range, 25.5–99.3) from RUX initiation, 4-year survival probability was 57.4% in aGVHD, 81.1% in classic cGVHD, and 78.6% in overlap cGVHD. Our findings reveal favorable survival probabilities associated with a long-term steroid-sparing/replacing potential of RUX in treatment-refractory aGVHD and cGVHD, including overlap syndrome and DLI-associated GVHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseasePyrazolesHematopoietic Stem Cell TransplantationHumansPyrimidinesNitrilesFemaleMaleAdultFollow-Up StudiesChronic DiseaseMiddle AgedAcute DiseaseYoung AdultAgedAdolescentTransplantation, Homologous

Stichwörter der Autor:innen

Donor lymphocyte infusion (DLI)Hematopoietic stem cell transplantationOverlap GVHDRefractory graft versus host diseaseRuxolitinib

Substanzen

ruxolitinibPyrimidinesNitrilesPyrazoles

Autor:innen und Institutionen

  • Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Fadingerstraße 1, Linz, 4020, Austria. raphael.loisl@ukr.de.
  • Medical Faculty, Johannes Kepler University, Linz, Austria. raphael.loisl@ukr.de.
  • Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, 93053, Germany. raphael.loisl@ukr.de.
  • Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Fadingerstraße 1, Linz, 4020, Austria. anna.bauhofer@ordensklinikum…
  • Medical Faculty, Johannes Kepler University, Linz, Austria. anna.bauhofer@ordensklinikum.at.
  • Department of Internal Medicine I: Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz - Elisabethinen, Fadingerstraße 1, Linz, 4020, Austria.

Förderung

  • Universitätsklinikum Regensburg

Zitieren

APA

Loisl, R., Bauhofer, A., Nikoloudis, A., Milanov, R., Machherndl-Spandl, S., Buxhofer-Ausch, V., Binder, M., Hasengruber, P., Kaynak, E., Wipplinger, D., Strassl, I., Saini, O., Aichinger, C., Petzer, A., Greinix, H., Wolff, D., & Clausen, J. (2026). Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease. Annals of Hematology, 105(8). https://doi.org/10.1007/s00277-026-07217-4

Vancouver

Loisl R, Bauhofer A, Nikoloudis A, Milanov R, Machherndl-Spandl S, Buxhofer-Ausch V, et al. Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease. Annals of Hematology. 2026;105(8). doi:10.1007/s00277-026-07217-4

BibTeX
@article{Loisl2026,
  author = {Loisl, Raphael and Bauhofer, Anna and Nikoloudis, Alexander and Milanov, Robert and Machherndl-Spandl, Sigrid and Buxhofer-Ausch, Veronika and Binder, Michaela and Hasengruber, Petra and Kaynak, Emine and Wipplinger, Dagmar and Strassl, Irene and Saini, Olga and Aichinger, Christoph and Petzer, Andreas and Greinix, Hildegard and Wolff, Daniel and Clausen, Johannes},
  title = {Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {8},
  doi = {10.1007/s00277-026-07217-4}
}
Kostenlos starten →